UNSPSC 51314104: Thonzylamine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H22N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K9YKD48Y4, chemically known as 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)pyrimidine hydrochloride, but more generally known as thonzylamine hydrochloride, which bears US NIH Compound Identifier 6136. European Medicines Agency schedules thonzylamine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10988MIG.

Most nations, for tariff purposes, schedule thonzylamine hydrochloride under HS 29335995. Thonzylamine hydrochloride bears US NLM identifiers UMLS ID C1563662 and NCI Concept Code C84205. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2NCCCN2.CL.

UNSPSC 51314104 Thonzylamine hydrochloride is a Commodity code that appears in state and local procurement activity focused on pharmaceutical products and drug-related support services, though the recent opportunities tagged under it do not match the code's nominal scope. The three recent solicitations posted between January and June 2026 show state and local bodies procurement naloxone (an opioid antagonist unrelated to thonzylamine), generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription program capabilities. The issuing bodies include a Florida county health system (Seminole County), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). None of the recent opportunities explicitly solicits thonzylamine hydrochloride by name or chemical specification, suggesting the code assignment may reflect a data-tagging error or a mislabeling in the source systems.

Activity is concentrated in the South and Upper Midwest. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023 (note: deadline date appears inconsistent with posting date). The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs for future formal solicitation. MMCAP, serving Minnesota and Oregon through the Minnesota Department of Administration's Office of State Procurement, released an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers. The mismatch between the code's stated product (thonzylamine hydrochloride) and the actual scope of these solicitations (naloxone, broad generic pharmaceuticals, and pharmacy benefit program infrastructure) suggests limited or misaligned recent activity under this specific commodity code.